SCFβ-TrCP1 controls Smad4 protein stability in pancreatic cancer cells

American Journal of Pathology

Volumn 166, Issue 5, 2005, Pages 1379-1392

  Wan, Mei ^a,b   Huang, Jin ^a   Jhala, Nirag C ^a   Tytler, Ewan M ^b   Yang, Lei ^a   Vickers, Selwyn M ^b   Tang, Yi ^a   Lu, Chongyuan ^a   Wang, Ning ^a   Cao, Xu ^a  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^b Kentucky   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

F BOX PROTEIN; LIGAND; MUTANT PROTEIN; PROTEIN SCF BETA TRCP1; SMAD4 PROTEIN; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CELL DIFFERENTIATION; CELL GROWTH; CONTROLLED STUDY; DPC4 GENE; GENE; GENE CLUSTER; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; REGULATORY MECHANISM; RETROVIRUS; SIGNAL TRANSDUCTION; UBIQUITINATION; VIRAL GENE DELIVERY SYSTEM;

EID: 20944440516     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)62356-5     Document Type: Article

References (66)

1. Farrow B, Evers BM: Inflammation and the development of pancreatic cancer. Surg Oncol Oxf 2002, 10:153-169
2. Devesa SS, Blot WJ, Stone BJ, Miller BA, Tarone RE, Fraumeni Jr JF: Recent cancer trends in the United States. J Natl Cancer Inst 1995, 87:175-182
3. Korc M: Role of growth factors in pancreatic cancer. Surg Oncol Clin N Am 1998, 7:25-41
4. Ozawa F, Friess H, Tempia-Caliera A, Kleeff J, Buchler MW: Growth factors and their receptors in pancreatic cancer. Teratog Carcinog Mutagen 2001, 21:27-44
5. Hruban RH, van Mansfeld AD, Offerhaus GJ, van Weering DH, Allison DC, Goodman SN, Kensler TW, Bose KK, Cameron JL, Bos JL: K-ras oncogene activation In adenocarcinoma of the human pancreas: a study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and altele-specific oligonucleotide hybridization. Am J Pathol 1993, 143:545-554
6. Barton CM, Staddon SL, Hughes CM, Hall PA, O'Sullivan C, Kloppel G, Theis B, Russell RC, Neoptolemos J, Williamson RC, Lane DP: Abnormalities of the p53 tumor suppressor gene in human pancreatic cancer. Br J Cancer 1991, 64:1076-1082
7. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ, Kern SE: Frequent somatic mulations and homozygous deletions of the p16 gene in pancreatic adenocarcinoma. Nat Genet 1994, 8:27-32
8. Yue J, Mulder KM: Transforming growth factor-β signal transduction in epithelial cells. Pharmacol Ther 2001, 91:1-34
9. Massague J, Blain SW, Lo RS: TGF-β signaling in growth control, cancer, and heritable disorders. Cell 2000, 103:295-309
10. Massague J: TGF-β signal transduction. Annu Rev Biochem 1998, 67:753-791
11. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH: DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996, 271:350-353
12. Schutte M, Hruban RH, Hedrick L, Cho KR, Nadasdy GM, Weinstein CL, Bova GS, Isaacs WB, Cairns P, Nawroz H: DPC4 gene in various tumor types. Cancer Res 1996, 56:2527-2530
13. Sunamura M, Yatsuoka T, Motoi F, Duda DG, Kimura M, Abe T, Yokoyama T, Inoue H, Oonuma M, Takeda K, Matsuno S: Gene therapy for pancreatic cancer based on genetic characterization of the disease. J Hepatobiliary Pancreat Surg 2002, 9:32-38
14. Tascilar M, Skinner HG, Rosty C, Sohn T, Wilentz RE, Offerhaus GJ, Adsay V, Abrams RA, Cameron JL, Kern SE, Yeo CJ, Hruban RH, Goggins M: The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res 2001, 7:4115-4121
15. Eppert K, Scherer SW, Ozcelik H, Pirone R, Hoodless P, Kim H, Tsui LC, Bapat B, Gallinger S, Andrulis IL: MADR2 maps to 18q21 and encodes a TGF-β-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 1996, 86:543-552
16. Shi Y, Hata A, Lo RS, Massague J, Pavletich NP: A structural basis for mutational inactivation of the tumour suppressor Smad4. Nature 1997, 388:87-93
17. Xu J, Attisano L: Mutations in the tumor suppressors Smad2 and Smad4 inactivate transforming growth factor beta signaling by targeting Smads to the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 2000, 97:4820-4825
18. Maurice D, Pierreux CE, Howell M, Wilentz RE, Owen MJ, Hill CS: Loss of Smad4 function in pancreatic tumors: c-terminal truncation leads to decreased stability. J Biol Chem 2001, 276:43175-43181
19. Moren A, Hellman U, Inada Y, Imamura T, Heldinn CH, Moustakas A: Differential ubiquitination defines the functional status of the tumor suppressor Smad4. J Biol Chem 2003, 278:33571-33582
20. DeSalle LM, Pagano M: Regulation of the G1 to S transition by the ubiquitin pathway. FEBS Lett 2001, 490:179-189
21. Pickart CM: Mechanisms underlying ubiquitination. Annu Rev Biochem 2001, 70:503-533
22. Deshaies RJ: SCF and Cullin/Ring H2-based ubiquitin ligases. Annu Rev Cell Dev Biol 1999, 15:435-467
23. Winston JT, Koepp DM, Zhu C, Elledge SJ, Harper JW: A family of mammalian F-box proteins. Curr Biol 1999, 9:1180-1182
24. Cardozo T, Pagano M: The SCF ubiquitin ligase: insights into a molecular machine. Nat Rev Mol Cell Biol 2004, 5:739-751
25. Yaron A, Hatzubai A, Davis M, Lavon I, Amit S, Manning AM, Andersen JS, Mann M, Mercuric F, Ben Neriah Y: Identification of the receptor component of the IκBα-ubiquitin ligase. Nature 1998, 396:590-594
26. Fuchs SY, Chen A, Xiong Y, Pan ZQ, Ronai Z: HOS, a human homolog of Slimb, forms an SCF complex with Skp1 and Cullin1 and targets the phosphorylation-dependent degradation of IκB and beta-catenin. Oncogene 1999, 18:2039-2046
27. Hatakeyama S, Kitagawa M, Nakayama M, Shirane M, Matsumoto M, Hattori K, Higashi H, Nakano H, Okumura K, Onoe K, Good RA: Ubiquitin-dependent degradation of IκBα is mediated by a ubiquitin ligase Skp1/Cul 1/F-box protein FWD1. Proc Natl Acad Sci USA 1999, 96:3859-3863
28. Spencer E, Jiang J, Chen ZJ: Signal-induced ubiquitination of IκBα by the F-box protein Slimb/β-TrCP. Genes Dev 1999, 13:284-294
29. Suzuki H, Chiba T, Kobayashi M, Takeuchi M, Suzuki T, Ichiyama A, Ikenoue T, Omata M, Furuichi K, Tanaka K: IκBα ubiquitination is catalyzed by an SCF-like complex containing Skp1, cullin-1, and two F-box/WD40-repeat proteins, βTrCP1 and βTrCP2. Biochem Biophys Res Commun 1999, 256:127-132
30. Winston JT, Strack P, Beer-Romero P, Chu CY, Elledge SJ, Harper JW: The SCFβ-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IkappaBalpha and beta-catenin and stimulates IκBα ubiquitination in vitro. Genes Dev 1999, 13:270-283
31. Hart M, Concordet JP, Lassot I, Albert I, del los Santos R, Durand H, Perret C, Rubinfeld B, Margottin F, Benarous R, Polakis P: The F-box protein β-TrCP associates with phosphorylated beta-catenin and regulates its activity in the cell. Curr Biol 1999, 9:207-210
32. Kitagawa M, Hatakeyama S, Shirane M, Matsumoto M, Ishida N, Hattori K, Nakamichi I, Kikuchi A, Nakayama K: An F-box protein, FWD1, mediates ubiquitin-dependent proteolysis of β-catenin. EMBO J 1999, 18:2401-2410
33. Latres E, Chiaur DS, Pagano M: The human F box protein beta-Trcp associates with the Cul1/Skp1 complex and regulates the stability of β-catenin. Oncogene 1999, 18:849-854
34. Lassot I, Segeral E, Berlioz-Torrent C, Durand H, Groussin L, Hai T, Benarous R, Margottin-Goguet F: ATF4 degradation relies on a phosphorylation-dependent interaction with the SCF(β-TrCP) ubiquitin ligase. Mol Cell Biol 2001, 21:2192-2202
35. Guardavaccaro D, Kudo Y, Boulaire J, Barchi M, Busino L, Donzelli M, Margottin-Goguet F, Jackson PK, Yamasaki L, Pagano M: Control of meiotic and mitotic progression by the F box protein β-Trcp1 in vivo. Dev Cell 2003, 4:799-812
36. βTrCP/Slimb ubiquitin ligase activates the anaphase promoting complex to allow progression beyond prometaphase. Dev Cell 2003, 4:813-826
37. Fong A, Sun SC: Genetic evidence for the essential role of beta-transducin repeat-containing protein in the inducible processing of NF-κB2/p100. J Biol Chem 2002, 277:22111-22114
38. Lang V, Janzen J, Fischer GZ, Soneji Y, Beinke S, Salmeron A, Allen H, Hay RT, Ben Neriah Y, Ley SC: βTrCP-mediated proteolysis of NF-κB p105 requires phosphorylation of p105 serines 927 and 932. Mol Cell Biol 2003, 23:402-413
39. Mantovani F, Banks L: Regulation of the discs large tumor suppressor by a phosphorylation-dependent interaction with the β-TrCP ubiquitin ligase receptor. J Biol Chem 2003, 278:42477-42486
40. Kumar KG, Tang W, Ravindranath AK, Clark WA, Croze E, Fuchs SY: SCF(HOS) ubiquitin ligase mediates the ligand-induced down-regulation of the interferon-alpha receptor. EMBO J 2003, 22:5480-5490
41. Busino L, Donzelli M, Chiesa M, Guardavaccaro D, Ganoth D, Dorrello NV, Hershko A, Pagano M, Draetta GF: Degradation of Cdc25A by beta-TrCP during S phase and in response to DNA damage. Nature 2003, 426:87-91
42. β-TRCP links Chk1 signaling to degradation of the Cdc25A protein phosphatase. Genes Dev 2003, 17:3062-3074
43. Watanabe N, Arai H, Nishihara Y, Taniguchi M, Watanabe N, Hunter T, Osada H: M-phase kinases induce phospho-dependent ubiquitination of somatic Wee1 by SCFβ-TrCP. Proc Natl Acad Sci USA 2004, 101:4419-4424
44. β-TrCP E3 ubiquitin ligase. Mol Cell Biol 2004, 24:4038-4048
45. Zhou BP, Deng J, Xia W, Xu J, Li YM, Gunduz M, Hung MC: Dual regulation of Snail by GSK-3β-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol 2004, 6:931-940
46. β-TrCP1. J Biol Chem 2004, 279:14484-14487
47. Sui G, Soohoo C, Affar EB, Gay F, Shi Y, Forrester WC, Shi Y: A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc Natl Acad Sci USA 2002, 99:5515-5520
48. Hameed M, Orrell RW, Cobbold M, Goldspink G, Harridge SD: Expression of IGF-1 splice variants in young and old human skeletal muscle after high resistance exercise. J Physiol 2003, 547:247-254
49. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB: Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987, 47:936-942
50. Lee DH, Goldberg AL: Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol 1998, 8:397-403
51. De Bosscher K, Hill CS, Nicolas FJ: Molecular and functional consequences of Smad4 C-terminal missense mutations in colorectal tumour cells. Biochem J 2004, 379:209-216
52. Zawel L, Dai JL, Buckhaults P, Zhou S, Kinzler KW, Vogelstein B, Kern SE: Human SmadS and Smad4 are sequence-specific transcription activators. Mol Cell 1998, 1:611-617
53. Feng XH, Lin X, Derynck R: Smad2, Smad3 and Smad4 cooperate with Sp1 to induce p15(lnk4B) transcription in response to TGF-β. EMBO J 2000, 19:5178-5193
54. Voss M, Wolff B, Savitskaia N, Ungefroren H, Deppert W, Schmiegel W, Kalthoff H, Naumann M: TGFβ-induced growth inhibition involves cell cycle inhibitor p21 and pRb independent from p15 expression. Int J Oncol 1999, 14:93-101
55. Peng B, Fleming JB, Breslin T, Grau AM, Fojioka S, Abbruzzese JL, Evans DB, Ayers D, Wathen K, Wu T, Robertson KD, Chiao PJ: Suppression of tumorigenesis and induction of p15(ink4b) by Smad4/ DPC4 in human pancreatic cancer cells. Clin Cancer Res 2002, 8:3628-3638
56. Imamura T, Kanai F, Kawakami T, Amarsanaa J, Ijichi H, Hoshida Y, Tanaka Y, Ikenoue T, Tateishi K, Kawabe T, Arakawa Y, Miyagishi M, Taira K, Yokosuka O, Omata M: Proteomic analysis of the TGF-β signaling pathway in pancreatic carcinoma cells using stable RNA interference to silence Smad4 expression. Biochem Biophys Res Commun 2004, 318:289-296
57. Ijichi H, Otsuka M, Tateishi K, Ikenoue T, Kawakami T, Kanai F, Arakawa Y, Seki N, Shimizu K, Miyazono K, Kawabe T, Omata M: Smad4-independent regulation of p21/WAF1 by transforming growth factor-β. Oncogene 2004, 23:1043-1051
58. Iacobuzio-Donahue CA, Song J, Parmiagiani G, Yeo CJ, Hruban RH, Kern SE: Missense mutations of MADH4: characterization of the mutational hot spot and functional consequences in human tumors. Clin Cancer Res 2004, 10:1597-1604
59. Shi Y, Hata A, Lo RS, Massague J, Pavletich NP: A structural basis for mutational inactivalion of the tumour suppressor Smad4. Nature 1997, 388:87-93
60. Eppert K, Scherer SW, Ozcelik H, Pirone R, Hoodless P, Kim H, Tsui LC, Bapat B, Gallinger S, Andrulis IL, Thomsen GH, Wrana JL. Attisano L: MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 1996, 86:543-552
61. de Caestecker MP, Yahata T, Wang D, Parks WT, Huang S, Hill CS, Shioda T, Roberts AB, Lechieider RJ: The Smad4 activation domain (SAD) is a praline-rich, p300-dependent transcriptional activation domain. J Biol Chem 2000, 275:2115-2122
62. Moren A, Itoh S, Moustakas A, Dijke P, Heldin CH: Functional consequences of tumorigenic missense mutations in the amino-terminal domain of Smad4. Oncogene 2000, 19:4396-4404
63. Shi X, Yang X, Chen D, Chang Z, Cao X: Smad1 interacts with homeobox DNA-binding proteins in bone morphogenetic protein signaling. J Biol Chem 1999, 274:13711-13717
64. Shi X, Bai S, Li L, Cao X: Hoxa-9 represses transforming growth factor-beta-induced osteopontin gene transcription. J Biol Chem 2001, 276:850-855
65. Wu L, Wu Y, Gathings B, Wan M, Li X, Grizzle W, Liu Z, Lu C, Mao Z. Cao X: Smad4 as a transcription compressor for estrogen receptor alpha. J Biol Chem 2003, 278:15192-15200
66. Shimizu K, Surdon JBA: A quantitative analysis of signal transduction from activin receptor to nucleus and its relevance to morphogen gradient interpretation. Proc Natl Acad Sci USA 1996, 96:6791-6796